GE Healthcare to Acquire Xcellerex
On Mar. 7, 2012, GE Healthcare announced an agreement to acquire Xcellerex, a supplier of manufacturing technologies for the biopharmaceutical industry, for an undisclosed amount.
On Mar. 7, 2012, GE Healthcare announced an agreement to acquire Xcellerex, a supplier of manufacturing technologies for the biopharmaceutical industry, for an undisclosed amount.
According to a press release, the acquisition will allow GE Healthcare to expand its offering of products and services for the manufacture of biopharmaceutical products such as recombinant proteins, antibodies, and vaccines. Xcellerex develops and produces turn-key biomanufacturing systems and production-scale bioreactors based around single-use components, including single-use bioreactor systems that are complementary to GE Healthcare’s products and range of media for cell culture. The companies believe that the strong strategic fit between the two companies, combined with expanded capabilities in product development and marketing, will offer significant customer benefits.
Nigel Darby, vice-president of BioTechnologies, and chief technology officer of GE Healthcare Life Sciences says in the release, “GE and Xcellerex share the vision that an integrated approach, where we can help customers optimize every stage of their manufacturing process, has the potential to increase production flexibility and to deliver higher yields of finished product while reducing time to market. With the global focus on spiraling health costs and the need for sustainable healthcare, these are critical issues for the industry.”
Guy Broadbent, president and CEO of Xcellerex, adds, “The integration of Xcellerex’s products with GE Healthcare’s complementary capabilities in upstream and downstream bioprocessing will help bring great benefits to our customers.”
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
